Charles River Laboratories Inte

Valuation Analysis

About the Company

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and sa

Charles River Laboratories Inte Stock at a Glance

Charles River Laboratories Inte (CRL) is currently trading at $187.51 with a market capitalization of $9B. The 52-week range spans from $143.06 to $228.88; the current price is 18.1% below the yearly high. Year-over-year revenue growth stands at +1.2%.

💰 Dividend

Charles River Laboratories Inte currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

15 analysts rate Charles River Laboratories Inte (CRL) on consensus: Buy. The average price target is $212.27, implying +13.2% from the current price. Analyst price targets range from $135.00 to $265.00.

Charles River Laboratories Inte: The Investment Case in Detail

Charles River Laboratories Inte (CRL) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 1.2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valuation in Context

With a PEG ratio of 0.12, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (9.34%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Charles River Laboratories Inte?

Compare top-rated brokers — low fees, trusted providers, fully regulated.